|Grant Number:||5R01CA111914-05 Interpret this number|
|Primary Investigator:||Pal, Tuya|
|Organization:||H. Lee Moffitt Cancer Ctr & Res Inst|
|Project Title:||Ovarian Cancer and Mismatch Repair Deficiency|
DESCRIPTION (provided by applicant): Ovarian cancer ranks fifth in both cancer incidence and cancer mortality in U.S. women and has the highest mortality rate among gynecologic cancers, with most patients presenting with late stage metastatic disease. Traditionally, most carcinomas have been treated as though they represent a single disease, and treatments have been based on stage and grade. Data is emerging that the response to treatments may differ, depending on the genetic etiology of the cancer. A better understanding of the molecular events that lead to the evolution of cancer and underlie tumor heterogeneity should lead to more specific treatment regimens. One of the best defined molecular pathways involved in both inherited and sporadic cancer pathogenesis involves the mismatch repair (MMR) pathway, which leads to microsatellite instability (MSI). MSI may result from both genetic (i.e.: germline mutations in the MMR genes, including MLH1, MSH2, and MSH6) and epigenetic (i.e.: MLH1 promoter hypermethylation) mechanisms. It is the purpose of the present proposal to quantify the proportion of ovarian tumors due to the mismatch repair genes and to characterize the tumors in this group. Our ability to classify ovarian cancers by their genetic basis offers promise for improvements in cancer prevention and screening of high risk women, in basing diagnosis and prognosis on molecular markers, and in development of individualized treatments. To date, only a few small studies of MMR in ovarian cancer have been performed and none have been population-based. This is in part due to the difficulty in recruiting large numbers of patients with ovarian cancer who are representative of the population. The proposed study is feasible to conduct only because of the extensive resources already available through the use of data and samples from three existing North American population-based studies, representing the majority of population-based cases in North America to date. This study will include 2200 incident epithelial ovarian cancers based at the Moffitt Cancer Center, Duke Comprehensive Cancer Center, and the University of Toronto and will be the largest collection of its type in the world. Paraffin-embedded tumor samples will be analyzed from all subjects with incident ovarian cancers to perform MSI testing and investigate MMR gene protein expression. In those samples with MSI-H status or with loss of expression of MMR gene proteins, epigenetic (MLH1 promoter hypermethylation) and genetic (germline MMR mutations) will be investigated. The clarification of factors that determine the etiology of MSI-H ovarian tumors are relevant to up to one-fifth of patients who have this deadly disease, hence these data may serve to advance clinical practice in several areas, including risk stratification, behavioral modification, and eventually have therapeutic relevance.
Improved Survival In Brca2 Carriers With Ovarian Cancer
Authors: Pal T. , Permuth-Wey J. , Kapoor R. , Cantor A. , Sutphen R. .
Source: Familial Cancer, 2007; 6(1), p. 113-9.
A Review Of The Clinical Relevance Of Mismatch-repair Deficiency In Ovarian Cancer
Authors: Pal T. , Permuth-Wey J. , Sellers T.A. .
Source: Cancer, 2008-08-15 00:00:00.0; 113(4), p. 733-42.
Systematic Review And Meta-analysis Of Ovarian Cancers: Estimation Of Microsatellite-high Frequency And Characterization Of Mismatch Repair Deficient Tumor Histology
Authors: Pal T. , Permuth-Wey J. , Kumar A. , Sellers T.A. .
Source: Clinical Cancer Research : An Official Journal Of The American Association For Cancer Research, 2008-11-01 00:00:00.0; 14(21), p. 6847-54.
Sampling Strategies For Tissue Microarrays To Evaluate Biomarkers In Ovarian Cancer
Authors: Permuth-Wey J. , Boulware D. , Valkov N. , Livingston S. , Nicosia S. , Lee J.H. , Sutphen R. , Schildkraut J. , Narod S. , Parker A. , et al. .
Source: Cancer Epidemiology, Biomarkers & Prevention : A Publication Of The American Association For Cancer Research, Cosponsored By The American Society Of Preventive Oncology, 2009 Jan; 18(1), p. 28-34.
Frequency Of Mutations In Mismatch Repair Genes In A Population-based Study Of Women With Ovarian Cancer
Authors: Pal T. , Akbari M.R. , Sun P. , Lee J.H. , Fulp J. , Thompson Z. , Coppola D. , Nicosia S. , Sellers T.A. , McLaughlin J. , et al. .
Source: British Journal Of Cancer, 2012-11-06 00:00:00.0; 107(10), p. 1783-90.
Uncertainty In The Utility Of Immunohistochemistry In Mismatch Repair Protein Expression In Epithelial Ovarian Cancer
Authors: Coppola D. , Nicosia S.V. , Doty A. , Sellers T.A. , Lee J.H. , Fulp J. , Thompson Z. , Galeb S. , McLaughlin J. , Narod S.A. , et al. .
Source: Anticancer Research, 2012 Nov; 32(11), p. 4963-9.
Long-term Ovarian Cancer Survival Associated With Mutation In Brca1 Or Brca2
Authors: McLaughlin J.R. , Rosen B. , Moody J. , Pal T. , Fan I. , Shaw P.A. , Risch H.A. , Sellers T.A. , Sun P. , Narod S.A. .
Source: Journal Of The National Cancer Institute, 2013-01-16 00:00:00.0; 105(2), p. 141-8.
Risk Factors For Ovarian Cancers With And Without Microsatellite Instability
Authors: Segev Y. , Pal T. , Rosen B. , McLaughlin J.R. , Sellers T.A. , Risch H.A. , Zhang S. , Ping S. , Narod S.A. , Schildkraut J. .
Source: International Journal Of Gynecological Cancer : Official Journal Of The International Gynecological Cancer Society, 2013 Jul; 23(6), p. 1010-5.
Association Between Ihc And Msi Testing To Identify Mismatch Repair-deficient Patients With Ovarian Cancer
Authors: Lee J.H. , Cragun D. , Thompson Z. , Coppola D. , Nicosia S.V. , Akbari M. , Zhang S. , McLaughlin J. , Narod S. , Schildkraut J. , et al. .
Source: Genetic Testing And Molecular Biomarkers, 2014 Apr; 18(4), p. 229-35.
Survival In Women With Ovarian Cancer With And Without Microsatellite Instability
Authors: Segev Y. , Zhang S. , Akbari M.R. , Sun P. , Sellers T.A. , McLaughlin J. , Risch H.A. , Rosen B. , Shaw P. , Schildkraut J. , et al. .
Source: European Journal Of Gynaecological Oncology, 2015; 36(6), p. 681-4.